^
Association details:
| Biomarker: | BCL2 overexpression + MCL1 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + lisaftoclax (APG-2575) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Published date:
09/01/2020
Excerpt:
We observed that APG-2575 in combination with ibrutinib exhibited synergistic growth inhibition on BCL-2-overexpressing or BCL-2-intermediate and MCL-1-overexpressing cell lines OCI-LY8, OCI-LY1, and SU-DHL4...The combination of APG-2575 and ibrutinib significantly induced apoptosis compared with either drug alone, suggesting significant lethality of the combination.
DOI:
10.3727/096504020X15825405463920
